1
Young Stephen Clinton, Murray Christopher: Process for selecting candidate drug compounds. Proteus Molecular Design, January 14, 1998: EP0818744-A2 (27 worldwide citation)

The invention relates to a process for drug candidate identification, said process comprising the steps of: (1) obtaining a computerised representation of the three-dimensional structure of a binding site on the surface of a biological macromolecule; (2) generating a computerised model of the functi ...


2
James Alexander, James MacDonald Brewer: Vaccines containing non-ionic surfactant vesicles. Proteus Molecular Design, Pennie & Edmonds, October 21, 1997: US05679355 (25 worldwide citation)

Non-ionic surfactant vesicles (NSIV) with entrapped antigen act as potent immunological adjuvants and can produce antibody titers of the same order of magnitude as those using Freund's Complete Adjuvant. The invention provides vaccines comprising such vesicles. Preferably non-ionic surfactants are g ...


3
Robert Vincent Fishleigh, Barry Robson, Roger Paul Mee: Fragments of prion proteins. Proteus Molecular Design, Pennie & Edmonds, June 30, 1998: US05773572 (20 worldwide citation)

Synthetic polypeptides having at least one antigenic site of a prion protein are disclosed together methods for their use and manufacture and antibodies raised against such polypeptides. Diagnostic kits using the polypeptides and/or antibodies are also disclosed.


4
James Alexander, James MacDonald Brewer: Vaccines. Proteus Molecular Design, The University of Strathclyde, Bell Seltzer Intellectual Property Law Group of Alston & Bird, March 2, 1999: US05876721 (11 worldwide citation)

Vesicles comprising at least one non-ionic surfactant and at least one molecule having the ability to transport or facilitate the transport of fats, fatty acids and lipids across mucosal membranes. With entrapped antigen they can act as immunological adjuvants. Vaccines based therein are active oral ...


5
Robert Vincent Fishleigh, Barry Robson, Roger Paul Mee: Fragments of prion proteins. Proteus Molecular Design, Pennie & Edmonds, April 30, 2002: US06379905 (6 worldwide citation)

Synthetic polypeptides having at least one antigenic site of a prion protein, methods for their use and manufacture, antibodies raised against such polypeptides and diagnostic kits containing these polypeptides or antibodies.


6
Quensel Louis Bertrand: Microbiological testing.. Proteus Molecular Design, January 16, 1991: GB2233760-A (6 worldwide citation)

Apparatus for performing a plurality of microbiological tests comprising a layer of agar or other nutrient gel filling a plurality of channels which communicate with a common region from which the apparatus may be charged with liquid agar prior to use; characterised in that indicia are provided adja ...


7
Barry Robson, Robert V Fishleigh: LHRH hormones. Proteus Molecular Design, Foley & Lardner, April 27, 1999: US05897863 (5 worldwide citation)

An analogue of lutenising hormone-releasing hormone (LHRH) having the amino acid sequence: pGlg-His-Trp-Ser-Tyr-X-Len-Arg-Pro-Gly-Y-Z


8
Morrison Christopher, Robson Barry, Fishleigh Robert: Improvements in or relating to hormones.. Proteus Molecular Design, December 7, 1988: EP0293530-A2 (4 worldwide citation)

An analogue of lutenising hormone-releasing hormone (LHRH) having the amino acid sequence: pGlg-His-Trp-Ser-Tyr-X-Len-Arg-Pro-Gly-Y-Z wherein X represents Gly or a D-amino acid, Y represents one or more amino acid residues, which may be the same of different, and Z represents Cys or Tyr, such that t ...


9
Glover Francis James, Rushton Arthur, Young Stephen Clinton, Morgan Phillip John: Angiotensin derivatives. Proteus Molecular Design, December 15, 2004: EP1486505-A1

An angiotensin derivative comprising at least one angiotensin peptide moiety coupled to a peptide carrier-binding moiety which can be used for therapy and prophylaxis of conditions associated with the renin activated angiotensin system.


10
Fishleigh Robert Vincent, Robson Barry: Analogs of piscine lhrh. Proteus Molecular Design, December 8, 1993: GB2267496-A

An analog of piscine GnRH is disclosed having the amino acid sequence: pGlu-His-Trp-Ser-Tyr-W-Trp-Leu-Arg-Pro-Gly-X-Y-Z wherein W represents Gly or a D-amino acid, X represents a bond, or one or more amino acids which may be the same or different, Y represents Cys or Tyr or is absent, and Z is absen ...